H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 1 of 11
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
NCT07694986
Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors
NCT07447635
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
NCT07476001
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
NCT07357298
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
NCT07194044
Digoxin Medulloblastoma Study
NCT06701812
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT06961357
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
NCT07250087
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
NCT07276386
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
NCT07222995
A First-in-Human Study of FID-022 in Solid Tumor Patients
NCT07249775
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
NCT07047885
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
NCT07030400
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
NCT07018986
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
NCT07007273
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
NCT06745882
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
NCT06047977
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
NCT06947083
ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area
NCT07218848
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients
NCT06909357
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
NCT06553885
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT06833502
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
NCT06660355
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT06660368
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
NCT06511882
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT06121180
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT06691035
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
NCT06193486
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
NCT06745895
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
NCT06597565
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
NCT06560398
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
NCT06553872
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT06409390
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
NCT06497569
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
App for Reducing Cravings to Smoke
NCT06088498
Exercise Prehabilitation for Locoregional Esophageal Cancer
NCT06430346
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT06295159
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
NCT06423950
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
NCT06350318
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
NCT06337552
Avapritinib With Decitabine in Patients With SM-AHN
NCT06327685
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
NCT06423963
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
NCT06305676
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
NCT06109467
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06144606
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06104592
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets.Report a data error.